[KSCI] Korea Science Citation Index Service

http://dx.doi.org/10.4062/biomolther.2013.072

Targeting the Transforming Growth Factor-β Signaling in Cancer Therapy

Sheen, Yhun Yhong (College of Pharmacy, Ewha Womans University)
Kim, Min-Jin (College of Pharmacy, Ewha Womans University)
Park, Sang-A (College of Pharmacy, Ewha Womans University)
Park, So-Yeon (College of Pharmacy, Ewha Womans University)
Nam, Jeong-Seok (Laboratory of Tumor Suppressor, Lee Gil Ya Cancer and Diabetes Institute, Gachon University)

Publication Information

Biomolecules & Therapeutics / v.21, no.5, 2013 , pp. 323-331 More about this Journal

Abstract

TGF- ${\beta}$ pathway is being extensively evaluated as a potential therapeutic target. The transforming growth factor- ${\beta}$ (TGF- ${\beta}$ ) signaling pathway has the dual role in both tumor suppression and tumor promotion. To design cancer therapeutics successfully, it is important to understand TGF- ${\beta}$ related functional contexts. This review discusses the molecular mechanism of the TGF- ${\beta}$ pathway and describes the different ways of tumor suppression and promotion by TGF- ${\beta}$ . In the last part of the review, the data on targeting TGF- ${\beta}$ pathway for cancer treatment is assessed. The TGF- ${\beta}$ inhibitors in pre-clinical studies, and Phase I and II clinical trials are updated.

Keywords

Transforming growth factor- ${\beta}$ (TGF- ${\beta}$ ); EW-7197; ALK5; Breast cancer; Metastasis;

Citations & Related Records

Reference

1	Park, C. Y., Kim, D. K. and Sheen, Y. Y. (2011b) EW-7203, a novel small molecule inhibitor of transforming growth factor- ${\beta}$ (TGF- ${\beta}$ ) type I receptor/activin receptor/like kinase-5, blocks TGF- ${\beta}1$ - mediated epithelial-to-mesenchymal transition in mammary epithelial cells. Cancer Sci. 102, 1889-1896. DOI ScienceOn
2	Parsons, R., Myeroff, L. L., Liu, B., Willson, J. K., Markowitz, S. D., Kinzler, K. W. and Vogelstein, B. (1995) Microsatellite instability and mutations of the transforming growth factor ${\beta}$ type II receptor gene in colorectal cancer. Cancer Res. 55, 5548-5550.
3	Peng, H., Carretero, O. A., Vuljaj, N., Liao, T.-D., Motivala, A., Peterson, E. L. and Rhaleb, N.-E. (2005) Angiotensin-converting enzyme inhibitors a new mechanism of action. Circulation 112, 2436-2445. DOI ScienceOn
4	Porter, P. L. (2009) Global trends in breast cancer incidence and mortality. Salud Publica Mex. 51, s141-s146. DOI
5	Roberts, A. B. and Wakefield, L. M. (2003) The two faces of transforming growth factor ${\beta}$ in carcinogenesis. Proc. Natl. Acad. Sci. U.S.A. 100, 8621-8623. DOI ScienceOn
6	Meulmeester, E. and ten Dijke, P. (2011). The dynamic roles of TGF- ${\beta}$ in cancer. J. Pathol. 223, 205-218.
7	Micalizzi, D. S., Christensen, K. L., Jedlicka, P., Coletta, R. D., Barón, A. E., Harrell, J. C., Horwitz, K. B., Billheimer, D., Heichman, K. A. and Welm, A. L. (2009) The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF- ${\beta}$ signaling. J. Clin.Invest. 119, 2678-2690. DOI ScienceOn
8	Micalizzi, D. S., Wang, C.-A., Farabaugh, S. M., Schiemann, W. P. and Ford, H. L. (2010) Homeoprotein Six1 increases TGF- ${\beta}$ Type I receptor and converts TGF- ${\beta}$ signaling from suppressive to supportive for tumor growth. Cancer Res. 70, 10371-10380. DOI
9	Mishra, L., Derynck, R. and Mishra, B. (2005) Transforming growth factor- ${\beta}$ signaling in stem cells and cancer. Science 310, 68-71. DOI ScienceOn
10	Mohammad, K. S., Javelaud, D., Fournier, P. G., Niewolna, M., McKenna, C. R., Peng, X. H., Duong, V., Dunn, L. K., Mauviel, A. and Guise, T. A. (2011) TGF- ${\beta}$ -RI kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastases. Cancer Res. 71, 175-184. DOI
11	Moon, J., Kim, H., Cho, I., Sheen, Y. and Kim, D. (2006) IN-1130, a novel transforming growth factor- ${\beta}$ type I receptor kinase (ALK5) inhibitor, suppresses renal fibrosis in obstructive nephropathy. Kidney Int. 70, 1234-1243. DOI ScienceOn
12	Muraoka-Cook, R. S., Dumont, N. and Arteaga, C. L. (2005) Dual role of transforming growth factor ${\beta}$ in mammary tumorigenesis and metastatic progression. Clin. Cancer Res. 11, 937s-943s.
13	Muraoka, R. S., Dumont, N., Ritter, C. A., Dugger, T. C., Brantley, D. M., Chen, J., Easterly, E., Roebuck, L. R., Ryan, S. and Gotwals, P. J. (2002) Blockade of TGF- ${\beta}$ inhibits mammary tumor cell viability, migration, and metastases. J. Clin. Invest. 109, 1551-1559. DOI
14	Levy, L. and Hill, C. S. (2006) Alterations in components of the TGF- ${\beta}$ superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev. 17, 41-58. DOI ScienceOn
15	Lindley, L. E. and Briegel, K. J. (2010) Molecular characterization of $TGF{\beta}$ -induced epithelial-mesenchymal transition in normal finite lifespan human mammary epithelial cells. Biochem. Biophys. Res. Commun. 399, 659-664. DOI ScienceOn
16	Maliekal, T. T., Antony, M.-L., Nair, A., Paulmurugan, R. and Karunagaran, D. (2003) Loss of expression, and mutations of Smad 2 and Smad 4 in human cervical cancer. Oncogene 22, 4889-4897. DOI ScienceOn
17	Massague, J. (2008) $TGF{\beta}$ in cancer. Cell 134, 215-230. DOI ScienceOn
18	Mani, S. A., Guo, W., Liao, M.-J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., Brooks, M., Reinhard, F., Zhang, C. C. and Shipitsin, M. (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704-715. DOI ScienceOn
19	Markowitz, S., Wang, J., Myeroff, L., Parsons, R., Sun, L., Lutterbaugh, J., Fan, R. S., Zborowska, E., Kinzler, K. W. and Vogelstein, B. (1995) Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 268, 1336-1338. DOI ScienceOn
20	Massague, J. (2000) How cells read TGF- ${\beta}$ signals. Nat. Rev. Mol. Cell Biol. 1, 169-178. DOI ScienceOn
21	Massague, J. and Gomis, R. R. (2006) The logic of $TGF{\beta}$ signaling. FEBS Lett. 580, 2811-2820. DOI ScienceOn
22	Matsuyama, S., Iwadate, M., Kondo, M., Saitoh, M., Hanyu, A., Shimizu, K., Aburatani, H., Mishima, H. K., Imamura, T. and Miyazono, K. (2003) SB-431542 and Gleevec inhibit transforming growth factor- ${\beta}$ -induced proliferation of human osteosarcoma cells. Cancer Res. 63, 7791-7798.
23	Melisi, D., Ishiyama, S., Sclabas, G. M., Fleming, J. B., Xia, Q., Tortora, G., Abbruzzese, J. L. and Chiao, P. J. (2008) LY2109761, a novel transforming growth factor ${\beta}$ receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol. Cancer Ther. 7, 829-840. DOI ScienceOn
24	Hjelmeland, M. D., Hjelmeland, A. B., Sathornsumetee, S., Reese, E. D., Herbstreith, M. H., Laping, N. J., Friedman, H. S., Bigner, D. D., Wang, X.-F. and Rich, J. N. (2004) SB-431542, a small molecule transforming growth factor- ${\beta}$ -receptor antagonist, inhibits human glioma cell line proliferation and motility. Mol. Cancer Ther. 3, 737-745.
25	Kingsley, D. M. (1994) The TGF-beta superfamily: new members, new receptors, and new genetic tests of function in different organisms. Genes Dev. 8, 133-146. DOI ScienceOn
26	Kang, Y., He, W., Tulley, S., Gupta, G. P., Serganova, I., Chen, C.-R., Manova-Todorova, K., Blasberg, R., Gerald, W. L. and Massague, J. (2005) Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc. Natl. Acad. Sci. U.S.A. 102, 13909-13914. DOI ScienceOn
27	Kang, Y., Siegel, P. M., Shu, W., Drobnjak, M., Kakonen, S. M., Corden- Cardo, C., Guise, T. A. and Massague, J. (2003) A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3, 537-549. DOI ScienceOn
28	Kim, D.-K., Sheen, Y. Y., Jin, C., Park, C.-Y., Domalapally, S., Kota, S. R., Maddeboina, K. and Bala, S. V. (2011) 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors. Google Patents. PCT/KR2011/004631.
29	Kingsley, L. A., Fournier, P. G., Chirgwin, J. M. and Guise, T. A. (2007) Molecular biology of bone metastasis. Mol. Cancer Ther. 6, 2609-2617. DOI
30	Korpal, M., Yan, J., Lu, X., Xu, S., Lerit, D. A. and Kang, Y. (2009) Imaging transforming growth factor- ${\beta}$ signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat. Med. 15, 960-966. DOI ScienceOn
31	Lampropoulos, P., Zizi-Sermpetzoglou, A., Rizos, S., Kostakis, A., Nikiteas, N. and Papavassiliou, A. G. (2012) TGF-beta signalling in colon carcinogenesis. Cancer Lett. 314, 1-7. DOI ScienceOn
32	Lee, G. Y., Kenny, P. A., Lee, E. H. and Bissell, M. J. (2007) Three-dimensional culture models of normal and malignant breast epithelial cells. Nat. Methods 4, 359-365. DOI ScienceOn
33	Goggins, M., Shekher, M., Turnacioglu, K., Yeo, C. J., Hruban, R. H. and Kern, S. E. (1998) Genetic alterations of the transforming growth factor ${\beta}$ receptor genes in pancreatic and biliary adenocarcinomas. Cancer Res. 58, 5329-5332.
34	Hagedorn, H. G., Bachmeier, B. E. and Nerlich, A. G. (2001) Synthesis and degradation of basement membranes and extracellular matrix and their regulation by TGF- ${\beta}$ in invasive carcinomas (Review). Int. J. Oncol. 18, 669-681.
35	Gordon, M. S., Ilaria, R. Jr., de Alwis, D. P., Mendelson, D. S., McKane, S., Wagner, M. M., Look, K. Y. and LoRusso, P. M. (2013) A Phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound, administered as a 24-h continuous infusion in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 71, 21-27. DOI ScienceOn
36	Grady, W. M., Myeroff, L. L., Swinler, S. E., Rajput, A., Thiagalingam, S., Lutterbaugh, J. D., Neumann, A., Brattain, M. G., Chang, J. and Kim, S.-J. (1999) Mutational inactivation of transforming growth factor ${\beta}$ receptor type II in microsatellite stable colon cancers. Cancer Res. 59, 320-324.
37	Grady, W. M., Rajput, A., Myeroff, L., Liu, D. F., Kwon, K., Willis, J. and Markowitz, S. (1998) Mutation of the type II transforming growth factor- ${\beta}$ receptor is coincident with the transformation of human colon adenomas to malignant carcinomas. Cancer Res. 58, 3101-3104.
38	Hau, P., Jachimczak, P., Schlingensiepen, R., Schulmeyer, F., Jauch, T., Steinbrecher, A., Brawanski, A., Proescholdt, M., Schlaier, J. and Buchroithner, J. (2007) Inhibition of TGF- ${\beta}$ 2 with ap 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies. Oligonucleotides 17, 201-212. DOI ScienceOn
39	Heldin, C.-H., Miyazono, K. and Ten Dijke, P. (1997) TGF- ${\beta}$ signalling from cell membrane to nucleus through SMAD proteins. Nature 390, 465-471. DOI ScienceOn
40	Derynck, R. and Akhurst, R. J. (2007) Differentiation plasticity regulated by TGF- ${\beta}$ family proteins in development and disease. Nat. Cell Biol. 9, 1000-1004. DOI ScienceOn
41	Derynck, R., Akhurst, R. J. and Balmain, A. (2001) TGF- ${\beta}$ signaling in tumor suppression and cancer progression. Nat. Genet. 29, 117-129. DOI ScienceOn
42	Eppert, K., Scherer, S. W., Ozcelik, H., Pirone, R., Hoodless, P., Kim, H., Tsui, L.-C., Bapat, B., Gallinger, S. and Andrulis, I. L. (1996). MADR2 maps to 18q21 and encodes a $TGF{\beta}$ -regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 86, 543-552. DOI ScienceOn
43	Derynck, R. and Zhang, Y. E. (2003) Smad-dependent and Smad-independent pathways in TGF- ${\beta}$ family signalling. Nature 425, 577-584. DOI ScienceOn
44	Dong, M. and Blobe, G. C. (2006) Role of transforming growth factor- ${\beta}$ in hematologic malignancies. Blood 107, 4589-4596. DOI ScienceOn
45	Ehata, S., Hanyu, A., Fujime, M., Katsuno, Y., Fukunaga, E., Goto, K., Ishikawa, Y., Nomura, K., Yokoo, H. and Shimizu, T. (2007) Ki26894, a novel transforming growth factor- ${\beta}$ type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line. Cancer Sci. 98, 127-133. DOI ScienceOn
46	Fernandez, T., Amoroso, S., Sharpe, S., Jones, G. M., Bliskovski, V., Kovalchuk, A., Wakefi eld, L. M., Kim, S.-J., Potter, M. and Letterio, J. J. (2002) Disruption of transforming growth factor ${\beta}$ signaling by a novel ligand-dependent mechanism. J. Exp. Med. 195, 1247-1255. DOI
47	Flavell, R. A., Sanjabi, S., Wrzesinski, S. H. and Licona-Limón, P. (2010). The polarization of immune cells in the tumour environment by $TGF{\beta}$ . Nat. Rev. Immunol. 10, 554-567. DOI ScienceOn
48	Ganapathy, V., Ge, R., Grazioli, A., Xie, W., Banach-Petrosky, W., Kang, Y., Lonning, S., McPherson, J., Yingling, J. M. and Biswas, S. (2010) Targeting the transforming growth factor- ${\beta}$ pathway inhibits human basal-like breast cancer metastasis. Mol. Cancer 9, 122. DOI ScienceOn
49	Bueno, L., de Alwis, D. P., Pitou, C., Yingling, J., Lahn, M., Glatt, S. and Troconiz, I. F. (2008) Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF- ${\beta}$ kinase antagonist, in mice. Eur. J. Cancer 44, 142-150. DOI ScienceOn
50	Calone, I. and Souchelnytskyi, S. (2012) Inhibition of TGFbeta signaling and its implications in anticancer treatments. Exp. Oncol. 34, 9-16.
51	Capocasale, R. J., Lamb, R. J., Vonderheid, E. C., Fox, F. E., Rook, A. H., Nowell, P. C. and Moore, J. S. (1995) Reduced surface expression of transforming growth factor beta receptor type II in mitogen-activated T cells from Sezary patients. Proc. Natl. Acad. Sci. U.S.A. 92, 5501-5505. DOI
52	Chen, T., Yan, W., Wells, R. G., Rimm, D. L., McNiff, J., Leffell, D. and Reiss, M. (2001) Novel inactivating mutations of transforming growth factor- ${\beta}$ type I receptor gene in head-and-neck cancer metastases. Int. J. Cancer 93, 653-661. DOI ScienceOn
53	Connolly, E. C., Freimuth, J. and Akhurst, R. J. (2012) Complexities of TGF- ${\beta}$ targeted cancer therapy. Int. J. Biol. Sci. 8, 964-978. DOI
54	Connolly, E. C., Saunier, E. F., Quigley, D., Luu, M. T., De Sapio, A., Hann, B., Yingling, J. M. and Akhurst, R. J. (2011) Outgrowth of drug-resistant carcinomas expressing markers of tumor aggression after long-term $T{\beta}RI/II$ kinase inhibition with LY2109761. Cancer Res. 71, 2339-2349. DOI
55	DaCosta Byfield, S. D., Major, C., Laping, N. J. and Roberts, A. B. (2004) SB-505124 is a selective inhibitor of transforming growth factor- ${\beta}$ type I receptors ALK4, ALK5, and ALK7. Mol. Pharmacol. 65, 744-752. DOI ScienceOn
56	Datta, P. K. and Mann, J. R. (2008) Transforming growth factor- ${\beta}$ (TGF- ${\beta}$ ) signaling inhibitors cancer therapy in: Transforming Growth Factor- ${\beta}$ in Cancer Therapy. In Cancer Treatment and therapy, Volume II, pp.573-587, Human Press.
57	Biswas, S., Guix, M., Rinehart, C., Dugger, T. C., Chytil, A., Moses, H. L., Freeman, M. L. and Arteaga, C. L. (2007) Inhibition of TGF- ${\beta}$ with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. J. Clin. Invest. 117, 1305-1313. DOI
58	Akiyama, Y., Iwanaga, R., Saitoh, K., Shiba, K., Ushio, K., Ikeda, E., Iwama, T., Nomizu, T. and Yuasa, Y. (1997) Transforming growth factor beta type II receptor gene mutations in adenomas from hereditary nonpolyposis colorectal cancer. Gastroenterology 112, 33-39. DOI ScienceOn
59	Arteaga, C., Hurd, S., Winnier, A., Johnson, M., Fendly, B. and Forbes, J. (1993) Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression. J. Clin. Invest. 92, 2569-2576. DOI ScienceOn
60	Bandyopadhyay, A., Agyin, J. K., Wang, L., Tang, Y., Lei, X., Story, B. M., Cornell, J. E., Pollock, B. H., Mundy, G. R. and Sun, L.-Z. (2006) Inhibition of pulmonary and skeletal metastasis by a transforming growth factor- ${\beta}$ type I receptor kinase inhibitor. Cancer Res. 66, 6714-6721. DOI ScienceOn
61	Zhang, Y. and Derynck, R. (1999) Regulation of Smad signalling by protein associations and signalling crosstalk. Trends Cell Biol. 9, 274-279. DOI ScienceOn
62	Yang, Y.-A., Dukhanina, O., Tang, B., Mamura, M., Letterio, J. J., Mac-Gregor, J., Patel, S. C., Khozin, S., Liu, Z.-y. and Green, J. (2002) Lifetime exposure to a soluble TGF- ${\beta}$ antagonist protects mice against metastasis without adverse side effects. J. Clin. Invest. 109, 1607-1615. DOI
63	Yingling, J. M., Blanchard, K. L. and Sawyer, J. S. (2004) Development of TGF- ${\beta}$ signalling inhibitors for cancer therapy. Nat. Rev. Drug Discov. 3, 1011-1022. DOI ScienceOn
64	Zhang, B., Halder, S. K., Zhang, S. and Datta, P. K. (2009) Targeting transforming growth factor- ${\beta}$ signaling in liver metastasis of colon cancer. Cancer Lett. 277, 114-120. DOI ScienceOn
65	Wakefield, L. M. and Roberts, A. B. (2002) TGF- ${\beta}$ signaling: positive and negative effects on tumorigenesis. Curr. Opin. Genet. Dev. 12, 22-29. DOI ScienceOn
66	Uhl, M., Aulwurm, S., Wischhusen, J., Weiler, M., Ma, J. Y., Almirez, R., Mangadu, R., Liu, Y.-W., Platten, M. and Herrlinger, U. (2004) SD-208, a novel transforming growth factor ${\beta}$ receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res. 64, 7954-7961. DOI ScienceOn
67	van Meeteren, L. A., Thorikay, M., Bergqvist, S., Pardali, E., Stampino, C. G., Hu-Lowe, D., Goumans, M.-J. and ten Dijke, P. (2012) Anti-human activin receptor-like kinase 1 (ALK1) antibody attenuates bone morphogenetic protein 9 (BMP9)-induced ALK1 signaling and interferes with endothelial cell sprouting. J. Biol. Chem. 287, 18551-18561. DOI
68	Viloria-Petit, A. M., David, L., Jia, J. Y., Erdemir, T., Bane, A. L., Pinnaduwage, D., Roncari, L., Narimatsu, M., Bose, R. and Moffat, J. (2009) A role for the $TGF{\beta}$ -Par6 polarity pathway in breast cancer progression. Proc. Natl. Acad. Sci. U.S.A. 106, 14028-14033. DOI ScienceOn
69	Wendt, M. K., Smith, J. A. and Schiemann, W. P. (2010) Transforming growth factor- ${\beta}$ -induced epithelial-mesenchymal transition facilitates epidermal growth factor-dependent breast cancer progression. Oncogene 29, 6485-6498. DOI ScienceOn
70	Wang, D., Kanuma, T., Mizunuma, H., Takama, F., Ibuki, Y., Wake, N., Mogi, A., Shitara, Y. and Takenoshita, S. (2000) Analysis of specific gene mutations in the transforming growth factor- ${\beta}$ signal transduction pathway in human ovarian cancer. Cancer Res. 60, 4507-4512.
71	Wiercinska, E., Naber, H. P., Pardali, E., van der Pluijm, G., van Dam, H. and ten Dijke, P. (2011) The TGF- ${\beta}$ /Smad pathway induces breast cancer cell invasion through the up-regulation of matrix metalloproteinase 2 and 9 in a spheroid invasion model system. Breast Cancer Res. Treat. 128, 657-666. DOI ScienceOn
72	Yakicier, M., Irmak, M., Romano, A., Kew, M. and Ozturk, M. (1999) Smad2 and Smad4 gene mutations in hepatocellular carcinoma. Oncogene 18, 4879-4883. DOI
73	Subramanian, G., Schwarz, R. E., Higgins, L., McEnroe, G., Chakravarty, S., Dugar, S. and Reiss, M. (2004) Targeting endogenous transforming growth factor ${\beta}$ receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype 1. Cancer Res. 64, 5200-5211. DOI ScienceOn
74	Takenoshita, S., Tani, M., Nagashima, M., Hagiwara, K., Bennett, W. P., Yokota, J. and Harris, C. C. (1997) Mutation analysis of coding sequences of the entire transforming growth factor beta type II receptor gene in sporadic human colon cancer using genomic DNA and intron primers. Oncogene 14, 1255-1258. DOI
75	Takeuchi, K., Abe, M., Hiasa, M., Oda, A., Amou, H., Kido, S., Harada, T., Tanaka, O., Miki, H. and Nakamura, S. (2010) TGF- ${\beta}$ inhibition restores terminal osteoblast differentiation to suppress myeloma growth. PLoS One 5, e9870. DOI ScienceOn
76	Thuault, S., Valcourt, U., Petersen, M., Manfioletti, G., Heldin, C.-H. and Moustakas, A. (2006) Transforming growth factor- ${\beta}$ employs HMGA2 to elicit epithelial-mesenchymal transition. J. Cell Biol. 174, 175-183. DOI ScienceOn
77	Tanaka, H., Shinto, O., Yashiro, M., Yamazoe, S., Iwauchi, T., Muguruma, K., Kubo, N., Ohira, M. and Hirakawa, K. (2010) Transforming growth factor ${\beta}$ signaling inhibitor, SB-431542, induces maturation of dendritic cells and enhances anti-tumor activity. Oncol. Rep. 24, 1637-1643.
78	Thiery, J. P., Acloque, H., Huang, R. Y. and Nieto, M. A. (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139, 871-890. DOI ScienceOn
79	Thomas, D. A. and Massagué, J. (2005) TGF- ${\beta}$ directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8, 369-380. DOI ScienceOn
80	Travis, R. C., Reeves, G. K., Green, J., Bull, D., Tipper, S. J., Baker, K., Beral, V., Peto, R., Bell, J. and Zelenika, D. (2010) Gene-environment interactions in 7610 women with breast cancer: prospective evidence from the Million Women Study. Lancet 375, 2143-2151. DOI ScienceOn
81	Rowland-Goldsmith, M. A., Maruyama, H., Matsuda, K., Idezawa, T., Ralli, M., Ralli, S. and Korc, M. (2002) Soluble type II transforming growth factor- ${\beta}$ receptor attenuates expression of metastasis-associated genes and suppresses pancreatic cancer cell metastasis1. Mol. Cancer Ther. 1, 161-167. DOI
82	Sanchez-Elsner, T., Botella, L. M., Velasco, B., Corbi, A., Attisano, L. and Bernabeu, C. (2001) Synergistic cooperation between hypoxia and transforming growth factor- ${\beta}$ pathways on human vascular endothelial growth factor gene expression. J. Biol. Chem. 276, 38527-38535. DOI ScienceOn
83	Sanchez-Zamorano, L. M., Flores-Luna, L., Angeles-Llerenas, A., Romieu, I., Lazcano-Ponce, E., Miranda-Hernandez, H., Mainero-Ratchelous, F. and Torres-Mejía, G. (2011) Healthy lifestyle on the risk of breast cancer. Cancer Epidemiol. Biomarkers Prev. 20, 912-922. DOI ScienceOn
84	Shinto, O., Yashiro, M., Kawajiri, H., Shimizu, K., Shimizu, T., Miwa, A. and Hirakawa, K. (2010) Inhibitory effect of a $TGF\beta$ receptor type-I inhibitor, Ki26894, on invasiveness of scirrhous gastric cancer cells. Br. J. Cancer 102, 844-851. DOI ScienceOn
85	Sawyer, T. K. (2004) Novel oncogenic protein kinase inhibitors for cancer therapy. Curr. Med. Chem. Anticancer Agents 4, 449-455. DOI ScienceOn
86	Schlingensiepen, K. H., Jaschinski, F., Lang, S. A., Moser, C., Geissler, E. K., Schlitt, H. J., Kielmanowicz, M. and Schneider, A. (2011) Transforming growth factor-beta 2 gene silencing with trabedersen (AP 12009) in pancreatic cancer. Cancer Sci. 102, 1193-1200. DOI ScienceOn
87	Shi, Y. and Massague, J. (2003) Mechanisms of TGF- ${\beta}$ signaling from cell membrane to the nucleus. Cell 113, 685-700. DOI ScienceOn
88	Shirakihara, T., Horiguchi, K., Miyazawa, K., Ehata, S., Shibata, T., Morita, I., Miyazono, K. and Saitoh, M. (2011) TGF- ${\beta}$ regulates isoform switching of FGF receptors and epithelial-mesenchymal transition. EMBO J. 30, 783-795. DOI ScienceOn
89	Nam, J.-S., Terabe, M., Mamura, M., Kang, M.-J., Chae, H., Stuelten, C., Kohn, E., Tang, B., Sabzevari, H. and Anver, M. R. (2008) An anti-transforming growth factor ${\beta}$ antibody suppresses metastasis via cooperative effects on multiple cell compartments. Cancer Res. 68, 3835-3843. DOI ScienceOn
90	Padua, D. and Massague, J. (2009) Roles of $TGF{\beta}$ in metastasis. Cell Res. 19, 89-102. DOI ScienceOn
91	Padua, D., Zhang, X. H.-F., Wang, Q., Nadal, C., Gerald, W. L., Gomis, R. R. and Massague, J. (2008) $TGF{\beta}$ primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 133, 66-77. DOI ScienceOn
92	Park, C.-Y., Son, J.-Y., Jin, C. H., Nam, J.-S., Kim, D.-K. and Sheen, Y. Y. (2011a) EW-7195, a novel inhibitor of ALK5 kinase inhibits EMT and breast cancer metastasis to lung. Eur. J. Cancer 47, 2642-2653. DOI ScienceOn

Reference

6	Eun-Ji Kim. (2016) Biomolecules & Therapeutics The Effect of (1S,2S,3E,7E,11E)-3,7,11,15-Cembratetraen-17,2-Olide (LS-1) from Lobophyyum sp. on the Apoptosis Induction of SNU-C5 Human Colorectal Cancer Cells / 24 (6) , 623
	Jennifer Pasquier. (2015) Journal of Oncology Epithelial to Mesenchymal Transition in a Clinical Perspective / 2015 , 1
2	Eun Ji Kim. (2015) Biomolecules & Therapeutics Cardamonin Suppresses TGF-β1-Induced Epithelial Mesenchymal Transition via Restoring Protein Phosphatase 2A Expression / 23 (2) , 141
6	Vesna Ivanović. (2016) Personalized Medicine Case with triple-negative breast cancer shows overexpression of both cFOS and TGF-β1 in node-positive tissue / 13 (6) , 523
3	Eun-Ji Kim. (2015) Marine Drugs The Anticancer Effect of (1S,2S,3E,7E,11E)-3,7,11, 15-Cembratetraen-17,2-olide(LS-1) through the Activation of TGF-β Signaling in SNU-C5/5-FU, Fluorouracil-Resistant Human Colon Cancer Cells / 13 (3) , 1340
	Sebastian Carotta. (2016) Frontiers in Immunology Targeting NK Cells for Anticancer Immunotherapy: Clinical and Preclinical Approaches / 7
1	Yi Yuan. (2017) Arthritis Research & Therapy Excessive activation of the TLR9/TGF-β1/PDGF-B pathway in the peripheral blood of patients with systemic lupus erythematosus / 19 (1)
1	B. Winkler. (2015) Pediatric Blood & Cancer TGFβ and IL10 have an impact on risk group and prognosis in childhood ALL / 62 (1) , 72
11	L Teng. (2015) Cancer Gene Therapy Conditioned media from human ovarian cancer endothelial progenitor cells induces ovarian cancer cell migration by activating epithelial-to-mesenchymal transition / 22 (11) , 518
7	Zhen Yan. (2017) International Journal of Gynecological Cancer Title Prognosis Significance of ZEB2 and TGF-β1 as well as Other Clinical Characteristics in Epithelial Ovarian Cancer / 27 (7) , 1343
	Jose M. Munoz-Felix. (2014) Expert Reviews in Molecular Medicine The role of endoglin in kidney fibrosis / 16
3	FEIFEI CHEN. (2016) Oncology Reports The emerging role of RUNX3 in cancer metastasis (Review) / 35 (3) , 1227
2	Deep Shah. (2016) Genes & Diseases Cancer stem cells and HER2 positive breast cancer: The story so far / 3 (2) , 114
5	Jorge Candia. (2016) Journal of Oral Research TGF-ß alterations in oral squamous cell carcinoma. Narrative review / 5 (5) , 207
1	Maria Villalba. (2017) Cell and Tissue Research Role of TGF-β in metastatic colon cancer: it is finally time for targeted therapy / 370 (1) , 29
1	Han Xiao. (2016) Scientific Reports Metformin is a novel suppressor for transforming growth factor (TGF)-β1 / 6 (1)
11	Shyam Kumar Gudey. (2014) Future Oncology Regulated intramembrane proteolysis of the TGFβ type I receptor conveys oncogenic signals / 10 (11) , 1853
1	Holli Loomans. (2015) Cancers Intertwining of Activin A and TGFβ Signaling: Dual Roles in Cancer Progression and Cancer Cell Invasion / 7 (1) , 70
6	Minsoo Koh. (2015) International Journal of Cancer Discoidin domain receptor 1 is a novel transcriptional target of ZEB1 in breast epithelial cells undergoing H-Ras-induced epithelial to mesenchymal transition / 136 (6) , E508
8	Inkyu Hwang. (2015) Archives of Pharmacal Research Mechanisms of tumor-induced T cell immune suppression and therapeutics to counter those effects / 38 (8) , 1415
12	Nan Sun. (2016) Journal of Clinical Medicine Switching Roles of TGF-β in Cancer Development: Implications for Therapeutic Target and Biomarker Studies / 5 (12) , 109
	Joanna Magdalena Zarzynska. (2014) Mediators of Inflammation Two Faces of TGF-Beta1 in Breast Cancer / 2014 , 1
	Xiao-yu Pan. (2015) Molecular and Cellular Endocrinology The mechanism and significance of synergistic induction of the expression of plasminogen activator inhibitor-1 by glucocorticoid and transforming growth factor beta in human ovarian cancer cells / 407 , 37
8	(2018) Cancers LY2157299 Monohydrate, a TGF-βR1 Inhibitor, Suppresses Tumor Growth and Ascites Development in Ovarian Cancer / 10 (8) , 260
39	(2013) Current pharmaceutical design The Role of TGF-β Signaling Regulatory MicroRNAs in the Pathogenesis of Colorectal Cancer / 24 (39) , 4611
2	(2018) Breast Cancer Research and Treatment Secretomes reveal several novel proteins as well as TGF-β1 as the top upstream regulator of metastatic process in breast cancer / 170 (2) , 235
5	(2019) Journal of Cellular Biochemistry Current status and future prospects of transforming growth factor-β as a potential prognostic and therapeutic target in the treatment of breast cancer / 120 (5) , 6962
8	(2013) The journal of immunology : official journal of the American Association of Immunologists Platelet-Derived Growth Factor Receptor Activation Promotes the Prodestructive Invadosome-Forming Phenotype of Synoviocytes from Patients with Rheumatoid Arthritis / 196 (8) , 3264
19	(2013) Cancer research : the official organ of the American Association for Cancer Research, Inc Stimulation of Natural Killer Cell-Mediated Tumor Immunity by an IL15/TGFβ-Neutralizing Fusion Protein / 76 (19) , 5683
None	(2017) Frontiers in pharmacology Mechanistic Study of Bakuchiol-Induced Anti-breast Cancer Stem Cell and <I>in Vivo</I> Anti-metastasis Effects / 8 (None) , 746
2	(2013) Bio-design and manufacturing ALK5 transfection of bone marrow mesenchymal stem cells to repair osteoarthritis of knee joint / 1 (2) , 135
5	(2013) Cancers Review: Targeting the Transforming Growth Factor-Beta Pathway in Ovarian Cancer / 11 (5) , 668
15	(2019) Aging Rejuvenation of brain, liver and muscle by simultaneous pharmacological modulation of two signaling determinants, that change in opposite directions with age / 11 (15) , 5628
18	(2020) Anti-cancer agents in medicinal chemistry New Entrants into Clinical Trials for Targeted Therapy of Breast Cancer: An Insight / 19 (18) , 2156
5	(2013) Cell death & disease Transgelin is a poor prognostic factor associated with advanced colorectal cancer (CRC) stage promoting tumor growth and migration in a TGFβ-dependent manner / 11 (5) , 341
3	(2013) Investigational new drugs : the journal of new anticancer agents Pharmacokinetic characteristics of vactosertib, a new activin receptor-like kinase 5 inhibitor, in patients with advanced solid tumors in a first-in-human phase 1 study / 38 (3) , 812
10	(2020) Pathology, research and practice Oxidative stress and TGF-β1 induction by metformin in MCF-7 and MDA-MB-231 human breast cancer cells are accompanied with the downregulation of genes related to cell proliferation, invasion and m / 216 (10) , 153135
12	(2013) Cancers Identification of Potential Serum Protein Biomarkers and Pathways for Pancreatic Cancer Cachexia Using an Aptamer-Based Discovery Platform / 12 (12) , 3787
None	(2013) Life sciences How transforming growth factor contributes to atrial fibrillation? / 266 (None) , 118823
2	(2013) Endocrinology A Positive Feedback Loop Between TGFβ and Androgen Receptor Supports Triple-negative Breast Cancer Anoikis Resistance / 162 (2) , bqaa226
3	(2013) Molecular therapy : the journal of the American Society of Gene Therapy TGFB1/INHBA Homodimer/Nodal-SMAD2/3 Signaling Network: A Pivotal Molecular Target in PDAC Treatment / 29 (3) , 920
4	(2013) Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology TGF‐β1 and IL‐17A comediate the protumor phenotype of neutrophils to regulate the epithelial‐mesenchymal transition in oral squamous cell carcinoma / 50 (4) , 353
None	(2013) Cytokine & growth factor reviews Role of TGF-β signaling in the mechanisms of tamoxifen resistance / 62 (None) , 62
1	(2013) Journal of translational medicine FOXO1 mitigates the SMAD3/FOXL2C134W transcriptomic effect in a model of human adult granulosa cell tumor / 19 (1) , 90
24	(2013) Cancers TGFβ Drives Metabolic Perturbations during Epithelial Mesenchymal Transition in Pancreatic Cancer: TGFβ Induced EMT in PDAC / 13 (24) , 6204